Kalaris Therapeutics (KLRS) vs. Its Peers Critical Contrast

Kalaris Therapeutics (NASDAQ:KLRS) is one of 618 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Kalaris Therapeutics to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Risk & Volatility

Kalaris Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics’ rivals have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Kalaris Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-81.02%	-65.15%
Kalaris Therapeutics Competitors	-1,434.00%	-642.77%	-28.21%

Insider and Institutional Ownership

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 75.0% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Kalaris Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kalaris Therapeutics	N/A	-$58.77 million	-1.16
Kalaris Therapeutics Competitors	$960.29 million	-$45.54 million	14.46

Kalaris Therapeutics’ rivals have higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kalaris Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1	1	2	1	2.60
Kalaris Therapeutics Competitors	5312	11928	37163	1120	2.61

Kalaris Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 144.16%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 67.49%. Given Kalaris Therapeutics’ higher probable upside, equities research analysts clearly believe Kalaris Therapeutics is more favorable than its rivals.

Summary

Kalaris Therapeutics rivals beat Kalaris Therapeutics on 7 of the 13 factors compared.

Kalaris Therapeutics Company Profile

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.